Shishir Pant
@pant-shishir.bsky.social
Postdoc @HarvardLab @harvardmed | Melanoma, Spatial biology, Multiplex imaging | PhD @helsinkiuni | Scientific writer @ACIR.org |🇳🇵🇫🇮🇺🇸
Reposted by Shishir Pant
Thanks to our readers who dive into it all — from experimental immunotherapy to cancer immunobiology to innovative methods 💙
You prove that science is stronger when we stay curious, stay current, and stay connected.
#CancerCure #ResearchMatters
You prove that science is stronger when we stay curious, stay current, and stay connected.
#CancerCure #ResearchMatters
July 1, 2025 at 11:30 AM
Thanks to our readers who dive into it all — from experimental immunotherapy to cancer immunobiology to innovative methods 💙
You prove that science is stronger when we stay curious, stay current, and stay connected.
#CancerCure #ResearchMatters
You prove that science is stronger when we stay curious, stay current, and stay connected.
#CancerCure #ResearchMatters
Reposted by Shishir Pant
For those who couldn't attend the new #AACRIO25 meeting, check out our digest here 👉 bit.ly/3XvBUkp. We included talks from @jimallisonphd.bsky.social, @danielathommen.bsky.social, @jcstark.bsky.social and more! (1/2)
March 5, 2025 at 4:30 PM
For those who couldn't attend the new #AACRIO25 meeting, check out our digest here 👉 bit.ly/3XvBUkp. We included talks from @jimallisonphd.bsky.social, @danielathommen.bsky.social, @jcstark.bsky.social and more! (1/2)
Reposted by Shishir Pant
Tailored cancer vaccine combined with PD-1 blockade in phase 1 trial @drcamidge.bsky.social bit.ly/40CHemx #immunoSky
January 29, 2025 at 3:55 PM
Tailored cancer vaccine combined with PD-1 blockade in phase 1 trial @drcamidge.bsky.social bit.ly/40CHemx #immunoSky
Reposted by Shishir Pant
Mok et al. evaluated the differences in memory responses between anti-CTLA-4 and anti-PD-1 to better understand why responses to anti-CTLA-4 last longer bit.ly/42oLGrD @mdanderson.bsky.social @jimallisonphd.bsky.social
January 22, 2025 at 4:45 PM
Mok et al. evaluated the differences in memory responses between anti-CTLA-4 and anti-PD-1 to better understand why responses to anti-CTLA-4 last longer bit.ly/42oLGrD @mdanderson.bsky.social @jimallisonphd.bsky.social
Reposted by Shishir Pant
Anti-TIGIT and anti-PD-L1 work together to support the generation of new antigen-specific T cells in dLNs, which then migrate to the blood, seed tumors, and help to mediate strong antitumor immunity bit.ly/3CcaM2d
January 8, 2025 at 4:30 PM
Anti-TIGIT and anti-PD-L1 work together to support the generation of new antigen-specific T cells in dLNs, which then migrate to the blood, seed tumors, and help to mediate strong antitumor immunity bit.ly/3CcaM2d
Reposted by Shishir Pant
A tetraspecific NK cell engager armed with IL-2v tops T cell engagers against B-NHL in preclinical studies 👉 acir.org/weekly-dige...
November 27, 2024 at 3:50 PM
A tetraspecific NK cell engager armed with IL-2v tops T cell engagers against B-NHL in preclinical studies 👉 acir.org/weekly-dige...
Reposted by Shishir Pant
Sectarianism in immunology.
(highly specific for immunologists, all credit to @pedromics on X)
1/8
(highly specific for immunologists, all credit to @pedromics on X)
1/8
November 25, 2024 at 7:35 PM
Sectarianism in immunology.
(highly specific for immunologists, all credit to @pedromics on X)
1/8
(highly specific for immunologists, all credit to @pedromics on X)
1/8
Here’s our comprehensive roundup of the most impactful research and key insights from the SITC Annual Meeting 2024.
acir.org/weekly-diges...
acir.org/weekly-diges...
SITC - 39th Annual Meeting 2024
This week’s extensive special feature covers select talks from the SITC - 39th Annual Meeting 2024 in Houston, TX. We have organized the content by topics below. Keynote lectureRafi Ahmed Harnessing i...
acir.org
November 20, 2024 at 1:17 PM
Here’s our comprehensive roundup of the most impactful research and key insights from the SITC Annual Meeting 2024.
acir.org/weekly-diges...
acir.org/weekly-diges...
To my friends and colleagues exploring career options in Europe
Pls share 🌟Join the IMP as a Group Leader
We are 👀 for a colleague, ready to lead a groundbreaking research program. Enjoy generous funding, outstanding facilities & a vibrant scientific community in one of the world's most livable cities @impvienna.bsky.social
👉https://tinyurl.com/impgl2025
November 20, 2024 at 11:40 AM
To my friends and colleagues exploring career options in Europe
Missed the AACR Tumor Immunology and Immunotherapy Meeting 2024 in Boston? Check out our special feature highlighting key talks and breakthroughs from the event
acir.org/weekly-diges...
acir.org/weekly-diges...
AACR Tumor Immunology and Immunotherapy Meeting 2024
This week’s extensive special feature covers select talks from the AACR Tumor Immunology and Immunotherapy Meeting 2024 in Boston. We have organized the content by topics below. Keynote lecturesSusan ...
acir.org
November 20, 2024 at 3:57 AM
Missed the AACR Tumor Immunology and Immunotherapy Meeting 2024 in Boston? Check out our special feature highlighting key talks and breakthroughs from the event
acir.org/weekly-diges...
acir.org/weekly-diges...